Company Overview and News

 
Internet of Things Inc Provides Corporate Update

2018-10-09 globenewswire
TORONTO, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Internet of Things Inc. (TSX VENTURE: ITT; OTC: INOTF; FRANKFURT: 7IT) (“ITT” or the “Company”) a strategic investor and operator of emerging technology companies with innovative IoT, AI and Blockchain solutions, is pleased to provide a corporate update detailing its recently accomplished milestones and growth initiatives.
INOTF MHC.H

97
The R.I.P. Portfolio's Q3 2018 Update

2018-10-01 seekingalpha
The portfolio has underperformed its benchmark so far in 2018, with several factors being significant contributors, but I believe that the portfolio is positioned to benefit from several major trends.
FB TWX MET PRU BAC TWTR KMG AAPL ACN INOTF GM INTC BAC GEC GE C ITT TWC CCMP GNE PFE

1
Acorn Energy's (ACFN) CEO Jan Loeb on Q2 2018 Results - Earnings Call Transcript

2018-08-15 seekingalpha - 1
Good day, everyone. Thank you for holding. And welcome to Acorn Energy's Second Quarter 2018 Conference Call. All participants are in a listen-only mode. [Operator Instructions]. After today's presentation, there will be an opportunity to ask questions. [Operator Instructions]. Please note that this event is being recorded.
ACFN ITT INOTF

1
Accenture's Q3 2018 Results: A Company That Is Firing On All Cylinders

2018-07-05 seekingalpha
The company is firing on all cylinders and investors should expect for more of the same in the quarters ahead.
ITT ACN INOTF

101
The R.I.P. Portfolio: Q2 2018 Update

2018-07-04 seekingalpha
The portfolio has underperformed its benchmark so far in 2018, with General Electric being a significant contributor, but it is properly positioned to benefit from several major trends.
FB TWX UAA MET KEY BAC TWTR AAPL ACN INOTF CAH INTC BAC GEC GE C ITT BHGE SYF TWC UA BHI TGT GNE

 
'You can’t undo that damage': How safe is your health data?

2018-06-30 theage.com.au
For the next three months, Australians have the chance to stop the government creating a digital medical health record with their information.
ITT INOTF

 
'You can’t undo that damage': How safe is your health data?

2018-06-30 smh.com.au
For the next three months, Australians have the chance to stop the government creating a digital medical health record with their information.
ITT INOTF

 
Internet of Things Inc. Closes Acquisition of Weather Telematics Inc.

2018-06-04 globenewswire
TORONTO and OTTAWA, June 04, 2018 (GLOBE NEWSWIRE) -- Internet of Things Inc. (TSX VENTURE:ITT) (OTC:INOTF) (FRANKFURT:71T) (“IoT Inc.” or the “Company”) a strategic investor and operator of emerging technology companies with innovative IoT, AI and Blockchain solutions, has completed the previously announced acquisition of Weather Telematics Inc. (“WTX Inc.” or “Weather Telematics”). WTX Inc. is a data science company offering real-time advanced artificial intelligence (AI) based predictive road condition weather analytics for safer, connected and autonomous transportation.
INOTF

 
Internet of Things Inc. to Acquire Weather Telematics Inc.

2018-05-14 globenewswire
TORONTO and OTTAWA, May 14, 2018 (GLOBE NEWSWIRE) -- Internet of Things Inc. (TSX VENTURE:ITT) (OTC:INOTF) (FRANKFURT:71T) (“IoT Inc.” or the “Company”) a strategic investor in growth-oriented companies with innovative IoT, AI and Blockchain solutions, is pleased to announce that it has entered into a letter agreement to acquire Weather Telematics Inc. (“WTX Inc.” or “Weather Telematics”) a data science company offering real-time advanced artificial intelligence (AI) based predictive road condition weather analytics for safer, connected and autonomous transportation.
INOTF

 
Internet of Things Inc. Hires James Sutcliffe as President & COO

2018-05-11 globenewswire
TORONTO, May 11, 2018 (GLOBE NEWSWIRE) -- Internet of Things Inc. (TSX VENTURE:ITT) (OTC:INOTF) (FRANKFURT:71T) (“IoT Inc.” or “the Company”) an IoT software and solutions provider targeting the Industrial IoT market, is pleased to announce the appointment of James Sutcliffe as President & COO. Mr. Sutcliffe will oversee operations, investee companies and work with management to expand its strategic plan to acquire and operate growth ready technology companies.
INOTF

 
BRIEF-Internet Of Things Received TSX Venture Approval For Joint Venture Agreement With New Hope Group

2018-04-13 reuters
* INTERNET OF THINGS INC. RECEIVED TSX VENTURE APPROVAL FOR JOINT VENTURE AGREEMENT WITH NEW HOPE GROUP Source text for Eikon: Further company coverage:
ITT INOTF

394
The R.I.P. Portfolio: Q1 2018 Update

2018-04-03 seekingalpha - 1
This real-money portfolio was first introduced to the Seeking Alpha community in December 2015 and it outperformed its benchmark in each of the last two years.
BAC GEC GE C ITT TWX MET TWC DWDP BAC TWTR AAPL ACN INOTF GNE INTC

12
Everyone is a Closet Technician

2018-03-29 thereformedbroker
Everyone is a closet technician. Everyone. And in a panic or a market correction, this truism is even more, um, truistic.
ITT INOTF MS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...